Compensation award — excluded from discretionary-purchase analysis.
Loading…
Traded Sep 15, 2026 · Filed Sep 17, 2026
Incyte's President, Global Head of R&D sold $1.11M of Incyte shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$1,112,577
Shares × reported transaction price
49 days after results of Jul 28, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $121.74 on Sep 15, 2026, 49% above its 52-week low and 6% below its high, after a 3% rise over the previous 30 trading days
52-week range $81.66 (Sep 25, 2025) to $129.93 (Jul 28, 2026), 83% of the way up, from 251 adjusted closes. 30 trading days earlier: $118.43 on Aug 3, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Atebrioz on Sep 25, 2026, 10 days after this trade.
New drug application approved. Active ingredient: Zilurgisertib. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -1.1% | +1.3% | -2.4% |
Past results only. Not a forecast.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
